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Human mesenchymal stem cells
Fibrous scaffolds
Amphiphilic polymerNative extracellular matrix (ECM) is a complex ﬁbrous structure loaded with bioactive cues that affects the sur-
rounding cells. A promising strategy tomimicking native tissue architecture for tissue engineering applications is
to engineer ﬁbrous scaffolds using electrospinning. By loading appropriate bioactive cues within these ﬁbrous
scaffolds, various cellular functions such as cell adhesion, proliferation and differentiation can be regulated.
Here, we report on the encapsulation and sustained release of a model hydrophobic drug (dexamethasone
(Dex)) within beaded ﬁbrillar scaffold of poly(ethylene oxide terephthalate)–poly(butylene terephthalate)
(PEOT/PBT), a polyether–ester multiblock copolymer to direct differentiation of human mesenchymal stem
cells (hMSCs). The amphiphilic beads act as depots for sustained drug release that is integrated into the ﬁbrillar
scaffolds. The entrapment of Dexwithin the beaded structure results in sustained release of the drug over the pe-
riod of 28 days. This is mainly attributed to the diffusion driven release of Dex from the amphiphilic electrospun
scaffolds. In vitro results indicate that hMSCs cultured on Dex containing beaded ﬁbrillar scaffolds exhibit an in-
crease in osteogenic differentiation potential, as evidenced by increased alkaline phosphatase (ALP) activity,
compared to the direct infusion of Dex in the culture medium. The formation of a mineralized matrix is also
signiﬁcantly enhanced due to the controlled Dex release from the ﬁbrous scaffolds. This approach can be used
to engineer scaffolds with appropriate chemical cues to direct tissue regeneration.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Native extracellularmatrix (ECM) is a complexﬁbrous structure that
provides physical, chemical, and mechanical cues to direct cellular
processes [1–5]. A promising strategy to mimic the native tissue archi-
tecture is to engineer ﬁbrous scaffolds using electrospinning (ESP) tech-
nique [6]. By incorporating appropriate topographical or therapeutic/
bioactive cues within the ﬁbrous scaffolds, various cellular processesfor Biomedical Engineering,
ital, Harvard Medical School,
ik@rics.bwh.harvard.educan be controlled to facilitate the formation of musculoskeletal tissues
[7–9]. For example, these ﬁbrous scaffolds could ﬁnd applications as
bone ﬁllers, in non-load bearing defects such as skull defects, or as
bone membranes such as in the case of periosteum regeneration
[7–9]. Electrospun scaffolds composed of hydroxyapatite/chitosan
have shown to promote new bone regeneration in vivo by activating
integrin and bone morphogenetic protein (BMP)/Smad signaling path-
way [10]. Fibrous membranes composed of gelatin/polycaprolactone
have shown to promote in vitro and in vivo cartilage tissue regeneration
[11]. In a similar study, ﬁbrous scaffoldsmade from poly(L-lactide-co-ε-
caprolactone)/collagen (P(LLA-CL)/Col) stimulated the differentiation
of tendon-derived stem cells when subjected tomechanical stimulation
[12].
Even when load bearing applications are considered, electrospun
scaffolds can be used in combinationwith, for example, rapid prototyped
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respect, the electrospun scaffolds can be useful to deliver biological fac-
tors that can augment, trigger, sustain and enhance the regenerative pro-
cess. Silk ﬁbroin based electrospun scaffolds loaded with bone
morphogenetic protein 2 (BMP-2) have shown to promote mineralized
matrix formation in vitro due to release of BMP-2 [14]. The surface of
electrospun ﬁbers can be functionalized to load appropriate bioactive
moieties to control cell fate [15–17]. To obtain a 3D porous network, a
range of techniques, such as the use of porogenic materials or water-
soluble agents are proposed [18]. After subjecting the electrospun scaf-
folds loaded with these agents to water, the desired porosity can be
achieved [18]. Another technique to enhance the porosity of electrospun
scaffolds includes laser ablation [19]. This technique allows incorporation
of micromachined pores with predetermined dimension and location to
improve cellular inﬁltration.
A range of hydrophobic or hydrophilic therapeutic agents can be
incorporated within electrospun ﬁbers by blending them with the
polymer solution prior to electrospinning [20–23]. The entrapped ther-
apeutic/bioactivemolecules can be released in vitro and in vivo as part of
the volumetric or surfacematrix or as a soluble factor in a sustained and
controlled manner to control cellular behaviors. For example, bioactive
agents such as BMPs [24,25], dexamethasone [26,27], hydroxyapatite
[28,29], calcium phosphate [30] and silicate nanoparticles [31–33] are
incorporatedwithin polymeric scaffolds to induce osteogenic differenti-
ation of stem cells. The release rate of these bioactive moieties can be
modiﬁed by altering the ﬁber morphology, degradation rate, hydrophi-
licity of polymer and drug loading [9,23,34,35].
Dexamethasone (Dex) is a synthetic member of the glucocorticoid
class of steroid drugs and is used in the treatment of severe inﬂammato-
ry diseases [36]. Dex has a concentration-dependent stimulatory effect
on the differentiation of human mesenchymal stem cells (hMSCs) [37,
38]. For example, hMSCs treatedwithDex show increased levels of alka-
line phosphatase (ALP) activity, which is an early marker for osteogenic
differentiation [39]. Furthermore, Dex is also known to enhance matrix
mineralization of hMSCs in combination with β-glycerolphosphate and
ascorbic acid [40]. Although the exact mode of action by which Dex
functions is unidentiﬁed, it is known that it enters the cell where it
binds to speciﬁc regulatory proteins, thereby, activating the transcrip-
tion of osteoblast-speciﬁc genes [26]. Although Dex is known to have
a prolonged effect on ALP expression and matrix mineralization even
after only a few days of exposure [41], continuous treatment of hMSCs
with Dex results in the most efﬁcient induction of differentiation and
subsequent matrix mineralization [42].
To control the release of Dex, various strategies such as encapsulation
(or entrapment/attachment) within poly(lactic-co-glycolic acid (PLGA)
microspheres [43], carbon nanotubes [44,45], poly(amidoamine)
(PAMAM) dendrimer nanoparticles [46] and hyperbranched polyester
hydrogels [47] have been reported. However, limited research has been
focused on controlled delivery of Dex from electrospun scaffolds
[48–51]. Martins et al. showed an increase in ALP expression and matrix
mineralization of hMSCs on electrospun polycaprolactone (PCL)/Dex
meshes in a basal medium containing β-glycerophosphate compared
to the unloaded meshes in an osteogenic medium [48,51]. This study
demonstrated that controlled release of Dex is an improvement over
normal dexamethasone-in-medium culture conditions [48,51]. Howev-
er, due to the crystalline nature of PCL, the sustained release of Dex
over long periods of time was not observed and a plateau phase was
reached within 4–5 days. This might be due to the formation of Dex ag-
gregates within the PCL scaffolds over time that results in limited release
of the entrapped drug. Moreover, the amount of Dex required to induce
osteogenic differentiationwas not compatiblewith the standard concen-
tration used in the established osteogenic differentiation protocols. At
the same time, it was shown that high concentrations of Dex could
impair cell proliferation and trigger the upregulation of adipogenesis in
parallel with osteogenesis (in vitro) [52]. Therefore, it is important to
tune Dex release rate from any carrier-device according to the strictrequirements to obtain an efﬁcient osteogenesis, followed by a robust
mineralization.
Recently, Nguyen et al. fabricated Dex loaded poly(L-lactic acid)
(PLLA) nanoﬁbrous scaffolds [49]. They also observed that the release
of Dex from these electrospun ﬁbers induces differentiation of hMSCs
over a period of 3 weeks. In a similar approach, Vacanti et al. entrapped
Dex within electrospun ﬁbers of PLLA and PCL [50]. Entrapped Dex was
released from PCL scaffolds within 24 h, whereas from PLLA a sustained
delivery for longer time frame was observed. They also demonstrated
that the localized in vivo delivery of Dex evoked a less severe inﬂamma-
tory response when compared with only PCL or PLLA ﬁbers.
Although, encapsulation of Dex in hydrophobic polymers such
as PCL and PLLA is described, to our knowledge the release of Dex
from amphiphilic polymers has not been reported. Amphiphilic block
polymers with tailored physical and chemical properties have shown
a controlled release proﬁle and linear degradation characteristics that
can be used for a range of tissue engineering applications [34,53,54].
We hypothesize that entrapping Dex within bead-like depots in an
amphiphilic ﬁbrillar scaffold will result in a sustained release proﬁle
over longer duration. Among amphiphilic copolymers, random block
copolymers of poly(ethylene oxide) terephthalate and poly(butylene
terephthalate) (PEOT/PBT) have been extensively investigated due to
their bioactive characteristics [34,55,56]. By varying the molecular
weight and polymer composition, a wide range of PEOT/PBT copolymer
with the desired mechanical strength, hydration properties, degrada-
tion proﬁles and biological characteristics can be obtained [57]. The
PEOT/PBT copolymers are biodegradable and have been proposed for
osteochondral tissue engineering [58–60]. 3D scaffolds from PEOT/PBT
were fabricated by using 3D ﬁber deposition (3DF) and electrospinning
(ESP) and showed to enhance cartilage tissue formation [61]. Due to the
amphiphilic nature of PEOT/PBT, it is predicted that hydrophobic drugs
(such as Dex) can be entrapped within the polymeric structure and
sustained release proﬁles from the ﬁbrillar structure can be obtained.
It is envisioned that such scaffold design can be used for a range of
musculoskeletal tissues engineering applications that require control
release of hydrophobic drugs to promote tissue regeneration.
In this study, electrospun scaffolds of PEOT/PBT containing different
loadings of Dexwere prepared. The surfacemorphologies of theseﬁbers
were examined by scanning electron microscopy (SEM). The entrap-
ment of Dex and in vitro release kinetics were investigated using
spectroscopic and chromatography techniques. The ability of Dex load-
ed ﬁbers to control hMSC adhesion, proliferation and differentiation
was also investigated. We hypothesize that hMSCs cultured on Dex
releasing scaffolds will show enhanced osteogenic differentiation com-
pared to the direct infusion of Dex in medium. The proposed approach
for directing cellular function by the sustained release of a hydrophobic
drug from amphiphilic ﬁbrous scaffolds can be used to engineer a range
of biomimetic scaffolds for controlled drug delivery and regenerative
medicine applications.
2. Experimental
2.1. Fabrication of PEOT/PBT electrospun scaffolds
PEOT/PBT was obtained from PolyVation B.V. (Groningen, The
Netherlands). The compositionused in this studywas 1000PEOT70PBT30
where, 1000 is the molecular weight in g/mol of the starting poly(ethyl-
ene glycol) (PEG) blocks used in the copolymerization, while 70 and 30
are the weight ratios of the PEOT and PBT blocks, respectively. PEOT is a
hydrophilic polymer that imparts elastomeric properties, whereas PBT
is a thermoplastic crystalline polymer and imparts stiffness to the copol-
ymeric network. Theﬁbrous scaffoldswere fabricated by ESP. First, PEOT/
PBT (20%w/v) was dissolved in a 9:1 ratio of anhydrous chloroform and
ethanol. ESP was carried out at 12.5 kV (Glassman High Voltage, INC)
using a 21G blunt needle and a ﬂow rate of 2 mL/h. The collector was a
circular plate (diameter 6.5 cm) made of aluminum and maintained at
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were dried overnight in vacuum to remove the residual solvent. For the
preparation of theDex loaded PEOT/PBT scaffolds, the drugwas dissolved
in ethanol (10× the desired ﬁnal concentration) and then dissolved in 9
parts of chloroform. PEOT/PBT solutions containing 0.5, 1 and 2% of Dex
(wt/wt) were prepared. ESP was carried out as described above.
2.2. Scanning electron microscopy
The size and morphologies of the electrospun ﬁbers were evaluated
using a scanning electron microscope (JSM 5600LV, JEOL USA Inc., MA).
The ﬁbers were allowed to dry in a desiccator for 24 h before imaging.
The scaffolds were coated with Au/Pd for 2 min using a Hummer 6.2
sputter coater (Ladd Research, Williston, VT). All images were captured
using 5 kV acceleration voltage and a working distance of 5–10 mm.
ImageJ software (National Institute of Health) was used to determine
the size of the ﬁbers from the SEM micrographs. The diameter of at
least 50 ﬁbers was measured from one image to determine the average
ﬁber diameter. The bead was excluded while determining the ﬁber
diameter of the electrospun ﬁbers. The bead density was calculated
manually by counting the number of beads in an image and then divid-
ing it by the total area.
2.3. Chemical characterization
Fourier transform infrared (FTIR) spectra of the samples were
recorded using an Alpha Bruker spectrometer. The average value of 48
scans at 4 cm−1 resolutions was collected for each sample. High-
performance liquid chromatography (HPLC) was performed to
determine the presence of Dex in electrospun scaffolds. The Water
600 system consisted of an automatic sample injector (Waters 717)
and a UV absorbance detector (Waters 2487) set at 254 nm. The
mobile phase consisted of acetonitrile. The analytical column was
3.9 mm× 300mm, and pore size 4 μm (Millipore Corp,Waters, Milford,
MA). The ﬂow rate was set at 1 mL/min. The retention time of Dex was
3.5 min, and the total run time of HPLC analysis was 10 min. The chro-
matograph was analyzed by Empower Pro software (Waters). For re-
lease kinetics studies, drug-loaded electrospun scaffolds (50 mg in
10 mL) were suspended in PBS in a dialysis tube (MWCO = 3500 Dal-
ton, Spectrum Lab). The dialysis tube was then suspended in 50 mL
PBS with gentle stirring. At predetermined time intervals, 1 mL portion
of PBS was collected for quantiﬁcation and replaced by equal volume of
PBS, and the release of Dex was quantiﬁed by HPLC. The thermal prop-
erties of scaffoldswere investigated using differential scanning calorim-
etry (DSC). The electrospun scaffold samples (3–5 mg in weight) were
sealed in an aluminum pan and were subjected to 2 heating/cooling
cycles from −70 °C to 100 °C at a heating rate of 10 °C/min under a
constant ﬂow of nitrogen at 20 mL/min. Protein adsorption was deter-
mined using micro bicinchoninic acid (micro BCA) protein assay
reagent (Pierce BCA, Thermo Scientiﬁc). Brieﬂy, electrospun
scaffolds were subjected to 10% fetal bovine serum (FBS) at 37 °C in
PBS for 24 h. Then samples were washed 3 times in PBS to extract
any non-speciﬁc adsorbed proteins and were treated with a 2% SDS
solution for 6 h in a shaker (50 rpm) to extract the adsorbed proteins.
The supernatant was collected separately and was analyzed using the
manufacturer's protocol.
2.4. Mechanical properties
The mechanical properties of electrospun scaffold were evaluated
using uniaxial tensile test using an Instron 5943 Materials Testing
System Capacity (Norwood, MA, USA) equipped with a 50 N load cell.
The samples were cut into rectangular shapes that were 10 mm long,
5 mm wide and approximately 100–150 μm thick. The samples were
stretched until failure at the crosshead speed of 10 mm/min. The elastic
modulus was calculated from the linear stress–strain region by ﬁtting astraight line between 5 and 20% strain. The ultimate tensile stress and
failure strain were also calculated.
2.5. In vitro cell culture studies
Bone marrow-derived hMSCs (PT-2501, Lonza) were cultured in
normal growth medium (a-MEM, containing 10% of heat-inactivated
fetal bovine serum (HiFBS, Gibco, USA) and 1% Pen/Strep (penicillin/
streptomycin, 100U/100 μg/mL, Gibco, USA)) at 37 °C, in a humidiﬁed
atmosphere with 5% CO2. Prior to cell seeding, the electrospun scaffolds
were sterilized using ethanol for 30 s before cell seeding, followed by
thorough washing with PBS. The cells were cultured until 70–75% con-
ﬂuence and were used before passage 4 for all the experiments. The
cells were trypsinized (CC-3232) and seeded on electrospun scaffolds
(1 × 1 cm2) at the density of 20,000 cells/scaffold in normal growthme-
dium. After 24 h, the electrospun PEOT/PBT scaffolds were subjected to
growth medium (−Dex) and osteogenic medium (+Dex), as negative
and positive control, respectively. Whereas, electrospun scaffolds were
containing Dex were subjected to medium (−Dex) to evaluate the ef-
fect of released Dex from the electrospun scaffolds on the hMSC
differentiation.
Cell proliferation over 21 days of culturewas evaluated usingAlamar
Blue Assay (Invitrogen) following the standard manufacturer protocol.
ALP activity was quantiﬁed using Alkaline Phosphatase Colorimetric
Assay Kit (Abcam, ab83369). The ALP enzyme in cell lysate converts p-
nitrophenol phosphate (pNPP) (present in kit) to yellow p-nitrophenol
(pNP) that can be easily detected using colorimetric assay. Brieﬂy,
samples and the assay buffer solution (5 mM pNPP) were added to a
96-well plate. After 1 h of incubation, the absorbance was read at
405 nm using a microplate reader (Epoch microplate reader, Biotek,
USA). A standard curve was made from standards (0–20 μM) prepared
with a pNPP solution. The samples and standard were analyzed and
sample concentrations were read from the standard curve (n = 3).
To detect the expression of ALP, nitro-blue tetrazolium/indolylphosphate
(NBT/BCIP) (Thermo Scientiﬁc) staining was also performed. Before
staining, the cells were washed with PBS, 0.5 mL of NBT/BCIP was
added and then the samples were incubated at 37 °C in a humidiﬁed
chamber containing 5% CO2. After 30 min, the samples were washed
with PBS and ﬁxed with 4% paraformaldehyde for imaging. The
optical images of stained scaffold were obtained using Zeiss Axio
Observer Z1 1 (AXIO1) equipped with a color camera (Evolve EMCCD
512 × 512 16 μm pixels).
2.6. Statistics
Experimental data were presented as mean± standard deviation
(n = 3 to 5). Statistical differences between the groups were
analyzed using one-way ANOVA with Tukey post-hoc analysis for
ﬁber analysis, mechanical testing and drug loading, and two-way
ANOVA for ALP analysis. Statistical signiﬁcance was represented as
*p b 0.05, **p b 0.01, ***p b 0.001.
3. Results and discussion
Electrospun ﬁbrous scaffolds are highly porous 3D network struc-
tures. The ﬁbrous scaffolds were obtained by ESP of PEOT/PBT copoly-
mer (Fig. 1a). Dex-loaded beaded structures were obtained by mixing
PEOT/PBT with different amounts of Dex (0, 0.5, 1 and 2% wt/wt Dex
compared to the polymer) before the ESP process (Fig. 1b). The effect
of Dex on the chemical, structural and biological properties of the
PEOT/PBT electrospun scaffolds was evaluated.
3.1. Amphiphilic beads integrated into ﬁbrillar scaffolds
Themorphology and size of electrospun ﬁbers were examined using
a scanning electron microscope (Fig. 1c). ESP of PEOT/PBT resulted in
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morphology. The addition of small amount of Dex (0.5%) resulted in
formation of beaded structures along the ﬁber. Moreover, a signiﬁcant
decrease in ﬁber diameter was observed due to addition of Dex. The ad-
dition of 0.5, 1 and 2% Dex signiﬁcantly decreases the ﬁber diameter to
0.61 ± 0.20, 0.62 ± 0.21 and 0.51 ± 0.22 μm respectively (Fig. 1d).
However, with the addition of Dex, the number of beadswithin the scaf-
fold structure increased (Fig. 1e). Thismight be attributed to an increase
in the conductivity of the polymeric solution due to the addition of Dex.
The number and size of beadswere quantiﬁed using image analysis and
results indicated that addition of the Dex resulted in an increase in the
number of beads without signiﬁcantly changing the beads dimension.
The formation of beads due to addition of Dex highlights that these
beads can act as drug depots or reservoirs integrated with the
electrospun ﬁbrous network. The entrapped drug from these depots
might release due to diffusion/degradation of ﬁbers within a controlled
fashion and subsequently control cellular behavior and functionality. To
determine the location of drug within these ﬁbrous structures, we
mixed Texas Red (a ﬂuorescence molecule with similar molecular
weight as Dex)with PEOT/PBT solution and fabricated electrospun scaf-
folds loaded with Texas Red. The microstructure analysis showed that
the addition of this ﬂuorescence dye instead of Dex did not result in
change in ﬁber morphology. By observing these beaded structures
under ﬂuorescence microscope, the location of dye within the ﬁbrous
structure was determined. Fig. 2a showed that the entrapped dye is
mainly located within the beaded structure, hence predicting the distri-
bution of Dex analogwithin the beaded units of the ﬁbers. This indicates
that the beaded structures effectively act as reservoirs of the dye or drug
molecule. Thus it can be expected that when Dex is mixed with PEOT/Fig. 1. Formation of electrospun beaded ﬁbers. (a) A schematic showing the formation of
electrospun scaffolds by combining PEOT/PBT with Dex. (b) The composition of
electrospun ﬁbers is listed. (c) The effect of Dex on ﬁber diameter and morphology was
evaluated using SEM. ESP of PEOT/PBT shows the formation of smooth and uniform ﬁbers.
The addition of a small amount of Dex results in ﬁbers with smaller diameters and beaded
structures. (d) The box plot representing distribution of ﬁber diameter is shown; the top
and the bottomof the box represent 25th and75th percentile respectively,whilewhiskers
representmin–max value of theﬁber diameter (n=60). (e) The addition of Dex results in
an increase in the number of beaded structures. The data representsmean± standard de-
viation. (One-way ANOVA with Tukey post-hoc, *p b 0.05, **p b 0.01, and ***p b 0.001).PBT, it might get accumulated within these beaded structure (depots)
and these depots were integrated within ﬁbrillar scaffolds.
The effect of the addition of Dex on the thermal and mechanical
properties of electrospun ﬁbers was also investigated using differential
scanning calorimetry (DSC) and uniaxial tensile test, respectively. The
thermal analysis of electrospun ﬁber indicated no effect on the melting
temperature (Tm)of PEOT/PBTdue to addition ofDex (Fig. 2b). Thismight
be due to a very low amount of Dexwithin the electrospun scaffold com-
pared to the amount of polymer. The addition of Dex resulted in a signif-
icant decrease in elastic modulus, ultimate tensile strength and
elongation of electrospun ﬁbers (Fig. 2c). This is mainly attributed to
the correspondent decrease in the ﬁber diameter due to the addition of
Dex.
3.2. Sustained release of Dex from beaded ﬁbrillar scaffolds
Incorporation of Dexwithin PEOT/PBT scaffoldswas evaluated using
high-performance liquid chromatography (HPLC) and Fourier trans-
form infrared spectroscopy (FTIR) (Fig. 3). The retention time of PEOT/
PBT was 3.5 min, and for Dex was 4.3 min. The electrospun ﬁbers con-
taining 2% Dex show peaks for both PEOT/PBT and Dex as shown in
Fig. 3a. The loading efﬁciency of Dex was also investigated by dissolving
the electrospun ﬁber. The results indicated that (Fig. 3b) PEOT/PBT
ﬁbers with 0.5, 1 and 2% Dex have loading of 2.1 ± 0.8, 8.3 ± 6.1
and 17.6 ± 9.3 μg of Dex/mg of PEOT/PBT, respectively. The loading ef-
ﬁciency of Dex in PEOT/PBT ﬁbers with 0.5, 1 and 2% Dexwas 42± 16%,
83 ± 61%, and 88 ± 46.5%, respectively. The loading efﬁciency was
lower compared to the theoretical value and this might be attributed
to the loss of Dex during the ESP process. Similar results were obtained
for the other types of drug during ESP [48].Fig. 2.Beaded structure as drug depotwithin ﬁbrillar scaffolds. (a) Schematics of the local-
ization of drug within ﬁber. To determine the localization of Dex within the ﬁbrillar struc-
ture, Dex was replaced with a ﬂuorescence dye “Texas Red” due to its similar molecular
weight with Dex. Addition of Texas Red (2% wt/wt) to PEOT/PBT forms a beaded ﬁbrillar
structure. Imaging techniques reveal distribution and localization of dye within the
beaded structures. Optical microscopy of electrospun ﬁbers loaded with Texas Red dis-
plays the beaded structure within ﬁbrillar scaffolds. The ﬂuorescence imaging indicates
that the dye is localizedwithin the beaded structure. SEM image of beaded ﬁbers showing
uniform distribution of beads within the ﬁbrous scaffolds of PEOT/PBT/2Dex. (b) Effect of
Dex on thermal property of PEOT/PBTwas investigated using DSC. No signiﬁcant inﬂuence
on the Tg of PEOT/PBTwas observed due to the addition of Dex. (c) Effect of Dex on theme-
chanical properties of PEOT/PBTﬁberswas evaluatedusing uniaxial tensile test. Formation
of the beaded structure due to addition of Dex results in a decrease inmechanical proper-
ties such as elastic modulus, tensile strength and ultimate strain. This might be attributed
to a decrease in the ﬁber diameter and formation of the beaded structure. The number of
beads present within a scaffold directly depends on the Dex concentration. The data rep-
resents mean ± standard deviation (n= 5).
70 A.K. Gaharwar et al. / Journal of Controlled Release 187 (2014) 66–73The presence of Dex within the electrospun ﬁbers was further
veriﬁed by FTIR and the spectra from Dex only, PEOT/PBT only and
Dex loaded PEOT/PBT are shown in Fig. 3c. A characteristic peak at
1660 cm−1 was observed in the loaded electrospun scaffolds indicating
the presence of Dex within the scaffolds. This observation is consistent
with earlier studies that reported the entrapment of Dex within
electrospunﬁbers [48]. The bioactive agents, such asDex, need to be de-
livered over a long period of time, within a controlled and systematic
fashion, to direct stem cells into desired lineages and promote the
formation of functional tissues [62]. The next generation of intelligent
tissue engineered scaffolds should not only facilitate cell adhesion,
spreading and proliferation, but should also direct cellular components
to synthesize ECM and perform according to the desired application,
contributing to the acquisition of biological performance and function.
The integration of instructive cues within tissue-engineered constructs
will allow a better control with less manipulations of the whole system
compared to the polymeric scaffolds.
Considering the above, the integration of Dex releasing feature
within the PEOT/PBT electrospun template enables the development
of a scaffold that can facilitate favorable cellular responses. Neverthe-
less, the release of drug/bioactive molecules from polymeric scaffold
depends on various factors such as microstructure of scaffold, polymer
composition, polymer hydrophilicity, drug loading capacity, degrada-
tion characteristic and polymer/drug interactions [63]. Thus, an ideal
scaffold should have sustained release of the entrapped drug to direct
the differentiation of cells. Moreover, it is also expected that the scaffold
should be biodegradable and have high porosity to promote cell migra-
tion and diffusion of nutrients and waste products. Compared to a bulk
polymer scaffold, electrospun scaffolds have a faster drug release
characteristic due to a larger surface area [17]. Moreover, the interactionFig. 3. Loading of Dex within PEOT/PBT ﬁbers. (a) Identiﬁcation of Dex and PEOT/PBT in
HPLC. The Dex peak appears at 4.2 min, whereas the PEOT/PBT peak appears around
3.3 min in HPLC. The Dex peak is quite far from the polymer peak and thus can be easily
identiﬁed. PEOT/PBT/2Dex have a peak for both polymer andDex indicating successful en-
trapment of drug within polymer scaffolds. (b) The loading of Dex within the polymeric
scaffold was determined by dissolving the electrospun scaffold. The results indicate high
entrapment efﬁciency of Dex within the ﬁbrillar scaffolds. (c) The presence of Dex within
the PEOT/PBT ﬁbers was also conﬁrmed by FTIR that shows a peak at 1660 cm−1. (d) The
release of Dex from the electrospun scaffold was monitored in physiological conditions
over the period of 28 days. The Dex released from the scaffolds is normalized to total
Dex loading (empirically determined). The results indicate a sustained release of Dex
from the ﬁbrillar scaffold after the initial burst release. The release kinetic data correlate
with the Korsmeyer–Peppas model of drug diffusion from the polymeric matrix. The re-
sults indicate Fickian diffusion of Dex from the ﬁbrillar structure, as the diffusion coefﬁ-
cient (n) is 0.33. The data represents mean ± standard deviation (n = 3).between polymer and water also plays an important role in drug load-
ing and release proﬁles. Previous studies reported that compared to hy-
drophobic or hydrophilic polymers, amphiphilic polymers have higher
drug loading and drug stability [64,65]. For example, hydrophilic drugs
have limited solubility in hydrophobic polymers and vice versa.Whereas,
amphiphilic polymers can strongly interact with many different types of
drugs and proteins and can entrap them within their polymeric struc-
ture [64,65].
Dex was entrapped within the ﬁbrous scaffolds by blend ESP. The
in vitro release of Dex from the electrospun scaffold containing 2% Dex
was monitored over a period of 28 days (Fig. 3d). Within the ﬁrst 24 h
a small burst release (~20%) of drug was observed. This initial burst
may be due to localization of drug near the ﬁber surface. After the initial
burst release, a sustained release of Dexwas observed over the course of
28 days, compatible with the concentrations that are usually employed
during standard osteogenic differentiation protocols (10−8 M). For ex-
ample, each scaffold was approximately 2–3 μg in weight and 500 μl
of medium was used for the in vitro study. The scaffold containing 2%
Dex will have ~46.8 ± 6.3 ng of Dex. According to the release proﬁle
and ignoring the burst release that corresponds to 20% of loaded Dex,
40% of Dex was released over the period of 28 days. For PEOT/PBT (2%
Dex), the 40% of the entire payload corresponds to 18.72 ± 2.52 ng of
Dex that was released over the period of 28 days. On other hand, if we
subject the cells to a constant Dex conc. of 10−8 M (1.962 ng/500 μl of
medium) for 28 days and change the medium every 3 days, then we
will be using ~17.658 ng of Dex. For PEOT/PBT scaffolds containing
0.5% and 1%Dex, the cumulative release of Dex ismuch lower compared
to the concentrations that are usually employed during osteogenic
differentiation.
The sustained release of Dex from PEOT/PBT scaffolds can be mainly
attributed to drug diffusion or polymer degradation, or a combination of
both. Earlier studies indicated that the PEOT/PBT copolymer starts to
degrade by hydrolysis and complete in vivo degradation occurs over a
period of 1 year [66]. Moreover, due to the amphiphilic nature of the
polymer, solvent driven diffusion of the drug is expected. To determine
the mechanism of Dex release from PEOT/PBT ﬁbers, the release kinetic
data was ﬁtted to the Korsmeyer–Peppas model (Mt/M∞= Ktn). Where
“Mt/M∞” is the fraction of Dex diffused at time “t”, “K” is the diffusion
rate constant and “n” is the diffusion exponent. The experimental data
were plotted as log (cumulative % drug release) versus log (time) as
shown in Fig. 3d. The result indicates that the value of “n” is 0.33, imply-
ing Fickian diffusion of Dex from the electrospun PEOT/PBT ﬁbrous ma-
trix. Thus, we believe that the sustained release of Dex is driven by
diffusion of the drug from the polymeric network.
3.3. Effect of sustained release of Dex on hMSC adhesion and proliferation
hMSCs are clinically relevant cells due to their multipotent nature
and self-renewal ability [67,68]. hMSCs are in continuous and dynamic
interaction with the surrounding extracellular matrix that dictates
their behavior and functionality. Earlier studies have shown that cells
elongate along the ﬁber axis and cellular morphology plays an impor-
tant role in cellular behavior [34,69]. The interaction between hMSCs
and electrospun scaffolds was evaluated by monitoring hMSC adhesion
and proliferation on scaffolds. All the scaffolds allowed cellular adhesion
and proliferation, as well as the organization of the cell body on the
ﬁbers. The cells were uniformly spread and elongated along the ﬁber
axis as determined by microscopic analysis and staining of the cells cy-
toskeleton (Fig. 4a). The ﬁber morphology plays an important role in
initial cell adhesion and spreading. It was observed that hMSCs readily
attached and spread on ﬁbers with a smaller ﬁber diameter (PEOT/PBT
with Dex) compared to PEOT/PBT. All the scaffolds showed adsorption
of protein when subjected to 10% FBS (Fig. 4b). Addition of Dex to
PEOT/PBT resulted in smaller ﬁber diameter and larger surface area;
this might be attributed to the enhanced protein adsorption on the
electrospun scaffolds.
Fig. 4. Adhesion and proliferation of hMSCs on PEOT/PBT ﬁbers. (a) hMSCs readily attach
and spread on the ﬁbrous structure. Cell bodies were stretched along the ﬁber axis. Com-
pared to PEOT/PBT ﬁbers, hMSCs were more spread on ﬁber containing Dex. (b) All the
electrospun ﬁbers adsorbed protein when submersed in 10% FBS. The ﬁbers containing
Dex (1 and 2%) were observed to adsorb more protein compared to PEOT/PBT. This
might be attributed to the enhanced surface area due to the small ﬁber diameter. (c)
The proliferation of hMSCs was monitored over 21 days. The proliferation temporal pro-
ﬁles are in harmony with the ones corresponding to cells in the positive control subset
(PEOT/PBT in (+Dex)medium). The proliferation data for all the sampleswas normalized
to proliferation of hMSCs on PEOT/PBT—day 3 (−Dex)medium. Thedata representsmean
± standard deviation (n= 3).
Fig. 5. Effect of Dex on ALP activity of hMSCs. hMSCs were cultured on the PEOT/PBT scaf-
fold in osteoconductive medium (−Dex) and osteoinductive (+Dex) medium. Whereas
PEOT/PBT scaffolds containing Dex were cultured only in osteoconductive (−Dex)
medium to evaluate the effect of Dex release on the ALP activity of hMSCs.
(a) hMSCs stained for surface ALP-positive cells after 21 days. A uniform distribution
of the ALP-positive cells on the scaffold can be observed, suggesting that the differen-
tiation occurs in a homogeneous manner. (b) ALP activity of hMSCs seeded on
electrospun scaffold was monitored over the period of 28 days. The ALP activity pro-
ﬁle along time presents a bell shape pattern, compatible with osteogenic differentia-
tion of hMSCs. Brieﬂy, no signiﬁcant effect of Dexwas observed on day 3. On day 7 and
14, scaffold-containing Dex show a signiﬁcantly higher ALP activity compared to the
negative control. On day 14, the scaffold containing 1% Dex shows highest ALP activ-
ity; followed by a sharp decrease, until day 28. This indicates that the sustained re-
lease of Dex from the polymeric scaffold triggers and sustains the osteogenic
differentiation of stem cells. The bars represent mean ± standard deviation (n = 3)
(One-way ANOVA with Tukey post-hoc, *p b 0.05, **p b 0.01 and ***p b 0.001).
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scaffolds onmetabolic activity, hMSCswere cultured in osteoconductive
(−Dex) and osteoinductive (+Dex) medium. The osteoconductive
(−Dex) medium contain β-glycerophosphate and ascorbic acid.
This medium formulation is able to support the functionality of
osteoblast-like cells, mainly their ability to deposit matrix that will
further be mineralized. The osteoinductive (+Dex) medium
contains β-glycerophosphate, ascorbic acid and dexamethasone.
The addition of Dex (10−8 M) will provide the biochemical trigger
towards the series of biochemical events that orchestrate the osteo-
genic differentiation. Within the scope of the study, the PEOT/PBT in
(−Dex) medium was used as negative control and PEOT/PBT in
(+Dex) medium was used as positive control.
During osteogenic differentiation, themetabolic activity of cells pos-
sesses a temporal component. During theﬁrst stage, the cells have an in-
creased proliferation rate that is followed by a decrease, due to the
switch of metabolism towards the osteogenic cellular commitment
and maturation [48–50]. The metabolic activity of hMSCs cultured on
electrospun PEOT/PBT scaffolds, monitored using Alamar Blue assay, is
depicted in Fig. 4c. The metabolic activity of hMSCs cultured on the
different experimental subsets showed a typical bell-shape pattern,
consistent with the hypothesis mentioned above. A signiﬁcant differ-
ence in the metabolic activity of hMSCs seeded on PEOT/PBT cultured
in the absence and presence of Dex could be observed. The suppression
of metabolic activity in PEOT/PBT (+Dex) compared to PEOT/PBT
(−Dex) is mainly attributed to the osteogenic differentiation of
hMSCs. Due to the addition of Dex to the PEOT/PBT scaffolds, a change
inmetabolic activity on day 7was observed. At lower Dex concentration(PEOT/PBT/0.5Dex) a signiﬁcant increase in metabolic activity was ob-
served. It might be possible that topography (smaller ﬁber diameter)
might be responsible for the enhanced metabolic activity. As the
amount of Dex increased, the metabolic activity of hMSCs decreased
(day 7). Taken together, these results highlight that PEOT/PBT
electrospun scaffolds support hMSC adhesion, spreading and prolifera-
tion,—primary requirements to promote relevant biological behaviors
in tissue engineering.
3.4. Effect of sustained release of Dex on osteogenic differentiation of hMSCs
The differentiation of hMSCs seeded on ﬁbrous scaffold was investi-
gated bymonitoring ALP activity over the course of 28 days (Fig. 5a and
b). ALP is a mid-stage checkpoint for the osteogenic differentiation,
whose expression proﬁle follows a temporal coordinate. An increase
of ALP activity normalized to the number of cells, until reaching a
“peak”, is accompanied by the matrix production. A decrease in the
ALP activity corresponds to the formation of mineral nucleation sites
that consist of inorganic calcium.
For the scaffoldswithout Dex, in (−Dex)medium, a residual ALP ac-
tivity was observed, that was kept constant during the experimental
time frame (Fig. 5b). However, with the increase of the Dex loading,
and therefore, with the increase of the released drug, an increase in
the ALP activity can be observed starting at day 7, until reaching a max-
imum value at day 14. At this time point, signiﬁcantly higher ALP activ-
ity of hMSCs was observed on ﬁbrous scaffolds containing 1% and 2%
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medium). The scaffolds containing 0.5% and 2%Dex showed ALP activity
similar to the positive control, indicating that the Dex release from the
scaffolds can trigger and sustain the commitment of hMSCs towards os-
teogenic differentiation. This also indicates that the rate of Dex release
from scaffolds has a similar or enhanced inﬂuence on up-regulation of
ALP activity when hMSCs are subjected to a continuous and constant
level of Dex.
To further evaluate the effect of Dex release on the differentiation of
hMSC, the extent of the production of a mineralized matrix was evalu-
ated, by the Alizarin Red staining [70]. The mineralized matrix consists
of calcium deposits, and underlines the osteoblast-like cells functional-
ity acquired by the differentiated hMSCs. This end-point is the hallmark
of complete stabilization and maturation of the differentiated cells.
Fig. 6 indicates that PEOT/PBT scaffolds without Dex (negative control)
did not induce osteogenic differentiation of hMSCs, whereas PEOT/PBT
scaffolds subjected to (+Dex) (positive control) facilitate the formation
of mineralized matrix. We further quantiﬁed the amount of the miner-
alized matrix by analyzing the area of the stained region (Fig. 6b). The
results correlated well with the ALP activity of hMSCs and the scaffolds
containing 1% Dex showed the highest area fraction of stained region
compared to all other scaffolds, whereas scaffolds containing 0.5 and
2% Dex have similar mineralized area fractions similar to the positive
control.Fig. 6.Effect of Dex onproduction of themineralizedmatrix. Alizarin Redwas used to stain
inorganic calcium deposition to identify production of the mineralized matrix by hMSCs.
PEOT/PBT cultured in (−Dex) medium does not show any mineralized matrix indicating
no spontaneous differentiation of seeded hMSCs. The PEOT/PBT in medium (+Dex)
showed the formation of themineralized matrix indicating production of the mineralized
matrix by seeded hMSCs acting as positive control. The addition of Dex to polymeric scaf-
folds signiﬁcantly enhances the production of the mineralized matrix. (b) The image
quantiﬁcation indicates that scaffolds containing 1% Dex showed the highest amount of
mineralized matrix on day 21 and 28 compared to the positive control PEOT/PBT in
(+Dex) medium. The data represents mean ± standard deviation (n= 3).4. Conclusions
We introduce electrospun scaffolds with a beaded structure as drug
reservoirs for tissue engineering applications. Dexamethasone, as a
model drug,was encapsulatedwithin PEOT/PBTmulti-block amphiphil-
ic copolymer and the effect of drug entrapment was investigated on
some of the physical, chemical and biological properties. The sustained
release of Dex from the beaded structure was observed over the course
of 21 days. The effect of the initial drug loads and the subsequent
sustained release of Dex on human bone marrow stem cell differentia-
tion were also investigated. The ﬁbrous scaffolds containing Dex upreg-
ulate ALP activity and facilitate the formation of themineralizedmatrix,
without the addition of Dex in the culture medium. The electrospun
scaffolds with a beaded ﬁbrous structure can potentially be used to
deliver bioactive agents for regenerative medicine within a controlled
and continuous fashion.Acknowledgments
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